Literature DB >> 12031549

Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+.

Stéphanie Barc1, Guylène Page, Laurence Barrier, François Huguet, Bernard Fauconneau.   

Abstract

MPTP or its metabolite MPP+ are used to produce a Parkinsonism syndrome in a variety of animal species. The present study describes the effects of intranigral MPP+ administration either at 10 or 40 microg on the neuronal dopamine transporter (DAT) activity measured in rat striatal synaptosomes at different times after lesion. The 40 microg MPP+ injection induced a maximal toxic effect on day 7. However, 10 microg MPP+ progressively inhibited DA uptake on the injured side. V(max) decreased in a time-dependent manner and the lowest value was observed on day 21 after lesion. At this time, the K(m) value began to increase and was continuously accentuated until day 45 as compared to the contralateral side. Treatments either with the antioxidant alpha-tocopherol acetate or the MAO inhibitor pargyline, given daily for 7 days after lesion, partially prevented the 40 microg MPP(+)-induced inhibition of DA uptake. Conversely, both treatments given daily for 21 days after lesion completely prevented the alteration of DAT activity in the ipsilateral striatum induced by 10 microg MPP+. The absence of protection when both treatments were stopped 2 weeks before DA uptake measurements indicated that free radicals and DA oxidized products were continuously accumulated and gradually affected the functionality of the DAT. These results demonstrate that a rat intranigral lesion with 10 microg MPP+ led to a progressive impairment of DAT activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031549     DOI: 10.1016/s0006-8993(02)02567-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

Review 1.  Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.

Authors:  Priyajit Banerjee; Ishita Saha; Diptendu Sarkar; Arpan Kumar Maiti
Journal:  Neurotox Res       Date:  2022-04-07       Impact factor: 3.911

Review 2.  Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities.

Authors:  Ana Patricia Duarte-Jurado; Yareth Gopar-Cuevas; Odila Saucedo-Cardenas; Maria de Jesus Loera-Arias; Roberto Montes-de-Oca-Luna; Aracely Garcia-Garcia; Humberto Rodriguez-Rocha
Journal:  Antioxidants (Basel)       Date:  2021-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.